Eisai和Biogen由于安全考虑,面临欧盟对阿尔茨海默氏病药物浸泡液的重新评估。 Eisai and Biogen face EU re-evaluation for Alzheimer's drug lecanemab due to safety concerns.

Eisai和Biogen正在等待欧盟批准用于早期阿尔茨海默氏病的药物Lecanemab。 Eisai and Biogen are awaiting approval for lecanemab, a drug for early Alzheimer's disease, in the EU. 虽然11月菲律宾人权委员会提出了积极的意见,但由于新的安全信息,欧洲委员会要求重新评估。 Though a positive opinion was given by the CHMP in November, the European Commission has requested a re-evaluation due to new safety information. 该药物已经在包括美国和日本在内的几个国家获得批准。 The drug is already approved in several countries including the U.S. and Japan. Eisai和Biogen正在与监管者合作,解决欧盟委员会的关切。 Eisai and Biogen are working with regulators to address the EC's concerns.